New and emerging therapeutic agents for the treatment of fibromyalgia: an update
Citations Over TimeTop 10% of 2010 papers
Abstract
Fibromyalgia (FM) is a chronic widespread pain condition that is estimated to affect 5 million US adults. Several molecular pathophysiologies are thought to contribute to the symptoms of FM, complicating the development of effective clinical management techniques. It is now known that abnormalities in both nociceptive and central pain processing systems are necessary (but perhaps not sufficient) to condition the onset and maintenance of FM, producing associated neuropsychologic symptoms such as pronounced fatigue, sleep abnormalities, cognitive difficulties, stress sensitivity, anxiety, and depression. Current treatment strategies are focused primarily on correcting the pathophysiologic mechanisms underlying these nervous system abnormalities. Clinical studies demonstrate the safety and efficacy of three drugs recently approved for the treatment of FM: pregabalin (an alpha-2-delta ligand), and duloxetine and milnacipran (serotonin/norepinephrine reuptake inhibitors). This review describes these pharmaceuticals in detail and discusses their current roles in FM management.
Related Papers
- → Duloxetine Compared with Pregabalin for Diabetic Peripheral Neuropathic Pain Management in Patients with Suboptimal Pain Response to Gabapentin and Treated with or without Antidepressants: A Post Hoc Analysis(2013)35 cited
- → Health Care Costs in Patients with Fibromyalgia on Pregabalin vs. Duloxetine(2011)15 cited
- → Efficacy of Pregabalin and Duloxetine in Patients with Painful Diabetic Peripheral Neuropathy (PDPN): A Multi-Centre Phase IV Clinical Trial—BLOSSOM(2023)6 cited
- → PMS7 DOSING PATTERN COMPARISON BETWEEN DULOXETINE AND PREGABALIN AMONG PATIENTS WITH FIBROMYALGIA(2009)
- → Efficacy of Pregabalin Versus Combined Pregabalin and Milnacipran in Fibromyalgia.(2019)